Glucagon News and Research

RSS

GLP-1 weight loss may reduce first-impression penalties in relationships and hiring

An NBER working paper found that GLP-1 initiation and associated weight loss were followed by higher partnership formation among initially single women and greater employment entry among women who were not employed. The findings suggest that part of the female obesity penalty may arise when prospective partners and employers form first impressions, although the observational analysis did not directly prove discrimination

13 Jul 2026

Nearly one in 10 Britons use or want weight-loss medication

The prevalence of GLP-1 receptor agonists for weight management in Great Britain highlights public interest and concerns over safety and prescribing practices.

13 Jul 2026

Study links GLP-1 treatment to fewer alcohol drinking days

Current GLP-1 receptor agonist prescriptions were associated with modestly lower AUDIT-C scores in a large, diverse US cohort. The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.

13 Jul 2026

Gut microbiota may shape eating behavior and guide new obesity treatments

The review shows how gut microbiota may influence appetite, food reward, inflammation, and energy balance through the gut-brain axis. Microbiota-targeted approaches could support future treatments for obesity and eating disorders, but clinical evidence remains limited.

12 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

GLP-1 exposure in pregnancy does not clearly raise major birth defect risk

A systematic review and meta-analysis of seven cohort studies involving more than 40,000 GLP-1 receptor agonist-exposed pregnancies found no statistically significant increase in major congenital malformations or several other adverse pregnancy outcomes. However, the evidence was low or very low certainty, and a urinary malformation signal based on unadjusted data requires cautious interpretation.

10 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

A 2026 State-of-the-Art review updates the ABCs of cardiovascular disease prevention to help clinicians apply contemporary risk assessment, lifestyle, pharmacologic, and cardiometabolic strategies in routine care. The framework emphasizes PREVENT™ risk equations, Life’s Essential 8, CKM syndrome, obesity care, lipid lowering, blood pressure control, healthy aging, heart failure prevention, and atrial fibrillation management.

7 Jul 2026

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

1 Jul 2026

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

18 Jun 2026

Gut microbes may help explain why obesity and type 2 diabetes become harder to reverse

This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, and extracellular vesicles, may shape obesity and type 2 diabetes through the microbiota-gut-brain axis.

17 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

The importance of ketones from a clinical and medical perspective

In this interview, News-Medical talks to Marcin Pacek, senior director of medical and scientific affairs in Europe for Nova Biomedical, about the importance of ketones in a medical and clinical setting.

From Nova Biomedical 15 Jun 2026

Glucagon News and Research

GLP-1 weight loss may reduce first-impression penalties in relationships and hiring

Nearly one in 10 Britons use or want weight-loss medication

Study links GLP-1 treatment to fewer alcohol drinking days

Gut microbiota may shape eating behavior and guide new obesity treatments

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

GLP-1 exposure in pregnancy does not clearly raise major birth defect risk

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

GLP-1 medications may improve long-term health for people with peripheral artery disease

Simple blood test could identify the most effective obesity drug

Semaglutide approval drove a surge in GLP-1 poison center exposures

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

Early diabetes drug treatment links to better survival after diagnosis thresholds

Researchers trace soaring poison control calls to semaglutide approval for weight loss

PMOS rethink reframes a common hormone disorder as a whole-body disease

Gut microbes may help explain why obesity and type 2 diabetes become harder to reverse

Weight-loss medications lessen the risk of violent criminal behavior

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

Tirzepatide outperforms semaglutide for real-world weight loss

The importance of ketones from a clinical and medical perspective

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News